Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | POLA1 | P09884 | 1/20 | 0.67 |
| ▸ | POLD1 | P28340 | 1/20 | 0.67 |
| ▸ | DTYMK | P23919 | 4/20 | 0.64 |
| ▸ | TYMS | P04818 | 2/20 | 0.62 |
| ▸ | TK1 | P04183 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839682 | 0.96 | POLB (0.77) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL1579556 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| SCHEMBL887725 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Telbivudine 5'Triphosphate SCHEMBL29725270 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL18785124 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL14279191 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL11055949 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| SCHEMBL21682516 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL21275938 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL77831 | 0.94 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | claimed |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | VISIGEN BIOTECHNOLOGIES, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9845500-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160244822-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation | 2016-08-25 | — | — | US | disclosed |
| US-9243284-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140127781-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation (US) | 2014-05-08 | — | — | US | disclosed |
| US-8648179-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130102050-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation (US) | 2013-04-25 | — | — | US | disclosed |
| US-8314216-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110184163-A1 | Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis | Life Technologies Corporation (US) | 2011-07-28 | — | — | US | disclosed |
| US-20100216122-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: METHODS FOR DIRECT DETECTION OF TAGGED MONOMERS | Life Technologies Corporation (US) | 2010-08-26 | — | — | US | disclosed |
| US-20070172860-A1 | Enzymatic nucleic acid synthesis: compositions and methods | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172869-A1 | Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172859-A1 | Enzymatic nucleic acid synthesis: methods for direct detection of tagged monomers | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1354064-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | Visigen Biotechnologies, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | Life Technologies Corporation | 2003-07-17 | — | — | US | disclosed |
| WO-2002044425-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| US-6399335-B1 | MIXING POLYMERASE AND NUCLEOSIDE TRIPHOSPHATE HAVING A GAMMA PHOSPHATE PHOSPHOESTER-LINKED FUNCTIONAL GROUP, INCUBATING SO THAT POLYMERASE CATALYZES CLEAVAGE BETWEEN ALPHA AND BETA PHOSPHATES AND LIBERATES PYROPHOSPHATE WITH FUNCTIONAL GROUP | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184163-A1 | Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis | RNGTT, PPA1, PNP | POLB 16/4885POLA1 40/4885POLD1 88/4885 |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | RNGTT, PPA1, PNP | POLB 13/4885POLA1 33/4885POLD1 70/4885 |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | RNGTT, PPA1, PNP | POLB 16/4885POLA1 41/4885POLD1 86/4885 |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | RNGTT, PNP, MTAP | POLB 16/4885POLA1 23/4885POLD1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.